Wealth Enhancement Advisory Services
IKT icon

Wealth Enhancement Advisory Services’s Inhibikase Therapeutics IKT Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3K Buy
+18,759
New +$33.6K ﹤0.01% 3956

Other funds holding IKT

TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SIC
SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wealth Enhancement Advisory Services's IKT Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Inhibikase Therapeutics (IKT) in Q2 2026: 18,759 shares worth $38.3K. The stake represents ﹤0.01% of the portfolio and ranks #3956 among its holdings.

5 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Wealth Enhancement Advisory Services held 18,759 shares of Inhibikase Therapeutics worth $38.3K as of Q2 2026.
  • Inhibikase Therapeutics was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #3956 holding.
  • 5 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.